South Korea
· Delayed Price · Currency is KRW Daehan Nupharm Statistics
Total Valuation
Daehan Nupharm has a market cap or net worth of KRW 108.77 billion. The enterprise value is 144.55 billion.
| Market Cap | 108.77B |
| Enterprise Value | 144.55B |
Important Dates
The next estimated earnings date is Monday, September 1, 2025.
| Earnings Date | Sep 1, 2025 |
| Ex-Dividend Date | Dec 27, 2024 |
Share Statistics
Daehan Nupharm has 14.04 million shares outstanding.
| Current Share Class | 14.04M |
| Shares Outstanding | 14.04M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 39.26% |
| Owned by Institutions (%) | 0.54% |
| Float | 8.24M |
Valuation Ratios
The trailing PE ratio is 8.48.
| PE Ratio | 8.48 |
| Forward PE | n/a |
| PS Ratio | 0.53 |
| PB Ratio | 0.86 |
| P/TBV Ratio | 0.87 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 10.14 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.55, with an EV/FCF ratio of -4.54.
| EV / Earnings | 11.27 |
| EV / Sales | 0.70 |
| EV / EBITDA | 6.55 |
| EV / EBIT | 8.06 |
| EV / FCF | -4.54 |
Financial Position
The company has a current ratio of 1.60, with a Debt / Equity ratio of 0.55.
| Current Ratio | 1.60 |
| Quick Ratio | 1.02 |
| Debt / Equity | 0.55 |
| Debt / EBITDA | 3.10 |
| Debt / FCF | -2.19 |
| Interest Coverage | 10.47 |
Financial Efficiency
Return on equity (ROE) is 10.50% and return on invested capital (ROIC) is 6.59%.
| Return on Equity (ROE) | 10.50% |
| Return on Assets (ROA) | 5.45% |
| Return on Invested Capital (ROIC) | 6.59% |
| Return on Capital Employed (ROCE) | 11.44% |
| Revenue Per Employee | 902.55M |
| Profits Per Employee | 56.27M |
| Employee Count | 228 |
| Asset Turnover | 0.97 |
| Inventory Turnover | 2.96 |
Taxes
In the past 12 months, Daehan Nupharm has paid 3.27 billion in taxes.
| Income Tax | 3.27B |
| Effective Tax Rate | 20.32% |
Stock Price Statistics
The stock price has decreased by -1.70% in the last 52 weeks. The beta is 0.51, so Daehan Nupharm's price volatility has been lower than the market average.
| Beta (5Y) | 0.51 |
| 52-Week Price Change | -1.70% |
| 50-Day Moving Average | 7,207.40 |
| 200-Day Moving Average | 7,373.25 |
| Relative Strength Index (RSI) | 46.63 |
| Average Volume (20 Days) | 410,162 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Daehan Nupharm had revenue of KRW 205.78 billion and earned 12.83 billion in profits. Earnings per share was 914.02.
| Revenue | 205.78B |
| Gross Profit | 97.29B |
| Operating Income | 18.42B |
| Pretax Income | 16.10B |
| Net Income | 12.83B |
| EBITDA | 22.54B |
| EBIT | 18.42B |
| Earnings Per Share (EPS) | 914.02 |
Balance Sheet
The company has 34.00 billion in cash and 69.78 billion in debt, giving a net cash position of -35.77 billion or -2,548.87 per share.
| Cash & Cash Equivalents | 34.00B |
| Total Debt | 69.78B |
| Net Cash | -35.77B |
| Net Cash Per Share | -2,548.87 |
| Equity (Book Value) | 126.40B |
| Book Value Per Share | 9,005.78 |
| Working Capital | 43.86B |
Cash Flow
In the last 12 months, operating cash flow was 10.73 billion and capital expenditures -42.54 billion, giving a free cash flow of -31.81 billion.
| Operating Cash Flow | 10.73B |
| Capital Expenditures | -42.54B |
| Free Cash Flow | -31.81B |
| FCF Per Share | -2,266.23 |
Margins
Gross margin is 47.28%, with operating and profit margins of 8.95% and 6.23%.
| Gross Margin | 47.28% |
| Operating Margin | 8.95% |
| Pretax Margin | 7.82% |
| Profit Margin | 6.23% |
| EBITDA Margin | 10.95% |
| EBIT Margin | 8.95% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 100.00, which amounts to a dividend yield of 1.33%.
| Dividend Per Share | 100.00 |
| Dividend Yield | 1.33% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 10.94% |
| Buyback Yield | n/a |
| Shareholder Yield | 1.33% |
| Earnings Yield | 11.79% |
| FCF Yield | -29.24% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Daehan Nupharm has an Altman Z-Score of 2.32 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.32 |
| Piotroski F-Score | 5 |